Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Utility Patent
1995-06-05
2001-01-02
Bansal, Geetha P. (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S194100, C424S195110, C424S196110, C424S197110, C424S277100, C424S278100, C530S412000, C530S413000, C530S828000, C514S002600, C514S021800
Utility Patent
active
06168793
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to a method of using heat shock protein 70 preparations obtained from tumor cells or cells infected with a virus or other agent in order to elicit an immune response against the tumor, virus or other agent.
BACKGROUND OF THE INVENTION
The observation that inbred mice and rats can be immunized against their own tumors or tumors of the same genetic background have led to a hypothesis that tumor-specific antigens exist. In essence, these studies showed that mice vaccinated with inactivated cancer cells are immune to subsequent challenges of live cancer cells. The phenomenon was shown to be individually tumor-specific, in that mice were immune specifically to the tumors used to immunize them and not to other tumors. The demonstration of immunogenicity of cancer cells led to a search for the cancer-derived molecules which elicit resistance to tumor challenges. The general approach in these experiments was to fractionate cancer-derived proteins and test them individually for their ability to immunize mice against the cancers from which the fractions were prepared.
One of the major difficulties in cancer immunotherapy has been the possibility that similar to the situation among animal cancers, each human cancer is different from all other cancers, i.e., human cancers, like cancers of experimental animals, are antigenically distinct. Clearly, there is some recent evidence for existence of common human tumor antigens (Kawakami et al., 1991, Darrow et al., 1989), and this augurs well for prospects of cancer immunotherapy. Nonetheless, in light of the overwhelming evidence from experimental and human systems, it is reasonable to assume that at the very least, human tumors would show tremendous antigenic diversity and heterogeneity.
The prospect of identification of the immunogenic antigens of individual tumors from cancer patients (or even of ‘only’ several different types of immunogenic antigens in case the antigens are shared), is daunting to the extent of being impractical. Numerous studies on vaccination against infectious diseases have shown that it is necessary to first identify and characterize the immunogenic antigens.
For the reasons described above, such a strategy is impractical for vaccination or other forms of immunotherapy against human cancers. Thus, there is a need to develop alternate methods for obtaining antigenic preparations which do not require such daunting identification of specific antigens from tumors of individual patients and avoids the difficulties and hazards associated with attenuation and inactivation of viruses.
SUMMARY OF THE INVENTION
This invention relates to an immunogenic composition comprising complexes of heat shock protein 70 and antigenic peptides derived from tumor cells or cells infected with a virus, bacteria or other agent. This invention also relates to a method of eliciting an immune response in a mammal comprising the steps of isolating heat shock protein 70-peptide complex from tumor cells or cells infected with a virus, bacteria or other agent and administering the heat shock protein 70-peptide complex to the mammal in an amount effective to elicit an immune response. The claimed invention provides a novel method of eliciting antigen-specific cellular immunity against tumors, endogenous antigens, bacterial and viral antigens.
This invention further relates to a method of preparing a heat shock protein 70-peptide complex capable of eliciting an immune response in a mammal comprising the steps of obtaining tumor cells from the mammal or cells which are infected with a virus, bacteria or other infectious agent, preparing an aqueous cell extract, purifying the extract through column chromatography and harvesting a heat shock protein 70-peptide complex in the absence of adenosine triphosphate (ATP).
This invention additionally relates to a method of preparing an antigenic peptide composition comprising obtaining cells from a mammal wherein the cells are tumor cells or cells infected with a virus, bacteria or other infectious agent, harvesting a heat shock protein 70-peptide complex from the cells wherein the heat shock protein 70-peptide complex is prepared in the absence of ATP and separating peptides from the heat shock protein 70-peptide complex, wherein the separated peptides are capable of eliciting an immune response in the mammal.
This invention also relates to an immunogenic composition comprising complexes of heat shock protein 70 and antigenic peptides derived from tumor cell lines or cell lines infected with a virus or bacteria. The invention further relates to a method of preparing a heat shock protein 70-peptide complex capable of eliciting an immune response in a mammal comprising preparing an aqueous cell extract from tumor cell lines or cell lines infected with a bacteria or virus, purifying the extract through column chromatography and harvesting a heat shock protein 70-peptide complex in the absence of ATP.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 5348945 (1994-09-01), Berberian et al.
patent: 5750119 (1998-05-01), Srivastava et al.
patent: 5830464 (1998-11-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: 5935976 (1999-08-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5985270 (1999-11-01), Srivastava
patent: 5991873 (1999-12-01), Srivastava et al.
patent: 6017540 (2000-01-01), Srivastava et al.
patent: 6030618 (2000-02-01), Srivastava
patent: 6048530 (2000-04-01), Srivastava
patent: 196 02 985 A1 (1997-07-01), None
patent: WO 94/03208 (1994-02-01), None
patent: WO 94/04676 (1994-03-01), None
patent: WO 94/11513 (1994-05-01), None
patent: WO 94/29459 (1994-12-01), None
patent: WO 97/06685 (1997-02-01), None
patent: WO 97/06828 (1997-02-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 97/26910 (1997-07-01), None
Udono et al. J. Exp. Med. 178:1391-96, Oct. 1993.
Blachere et al. Journal of Immunotherapy 14:352-56, 1993.
Barrios et al., 1994, “Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65kD”, Clin. Exp. Immunol., 98:224-228.
Barrios et al., 1994, “Heat shock protein as carrier molecules: in vivo helper effect mediated byEscherichida coliGroEl and DnaK proteins requires cross-linking with antigen”, Clin. Exp. Immunol., 98:229-233.
Blachere and Srivastava, 1993 “Immunization with GP96 Heat Shock Proteins Isolated from Tumors or Influenza Virus Infected Cells Elicits MHC-Restricted, Antigen-Specific Cytotoxic T Lymphocytes Against the Corresponding Cells/Antigens”, J. Cell. Biochem. Suppl. 17D:124 (Abstract NZ 502).
Flynn et al., 1989, “Peptide Binding and Release by Proteins Implicated as Catalysts of Protein Assembly”, Science 245:385-390.
Levinson et al., 1979, “Metal Binding Drugs Induce Synthesis of Four Proteins in Normal Cells” Biol. Trace Element Res. 1:15-23.
Martin et al., 1986, “Role of Murine Tumor Models in Cancer Treatment Research”, Cancer Res. 46:2189-2192.
Melief and Kast, 1996, “Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication in General”, Cancer Surveys 13:81-99.
Mul{acute over (e )}et al., 1984, “Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2”, Science 225:1487-1489.
Srivastava, 1993, “Evidence for Peptide-Chaperoning by the Endoplasmic Reticular Heat Shock Protein GP96: Implications for Vaccination Against Cancer and Infectious Diseases”, J. Cell. Biochem. Suppl. 17D:94 (Abstract NZ 014).
Thomas et al., 1992, “Molecular and Cellular Effects of Heat-Shock and Related Treatments of Mammalian Tissue Culture Cells”, Cold Spring Harbor Symp. Quant. Biol. 46:985-996.
Welch and Feramisco, 1982, “Purification of the Major Mammalian Heat Shock Proteins”, J. Biol. Chem. 257:14949-14959.
Lusson et al. Eur. J. Immunol. 21:2297-2302 1991.
Srivastava et al. Seminars in Immunology 3:57-64 1991.
Lakey et al. PNAS 84:1659-63 1987.*
Bansal Geetha P.
Mount Sinai School of Medicine of New York University
Pennie & Edmonds LLP
LandOfFree
Heat shock protein 70 preparations in vaccination against... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heat shock protein 70 preparations in vaccination against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heat shock protein 70 preparations in vaccination against... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2499843